Latest News in the pharma Industry
Research & Development
3D human sebaceous glands technology for skin care applications
9 Jan 2018
New 3D technology provides a powerful platform for skin care researchers wishing to study the function of sebaceous glands, in relation to a range of age-related, microbial and inflammatory skin disorders.
Read more.png)
Sangamo and Pfizer collaborate to develop zinc finger protein gene therapy for ALS
7 Jan 2018
"The precision and flexibility of zinc finger proteins enables targeting of virtually any genetic mutation."
Read more.png)
Promacta receives FDA Breakthrough Therapy designation for first-line use in severe aplastic anemia
4 Jan 2018
Data supporting designation showed over half of treatment-naïve SAA patients achieved complete response with Promacta when given with standard immunosuppressive therapy, with overall response rate of 85%.
Read more
Momenta and Mylan to development proposed biosimilar to Eylea
4 Jan 2018
Targeting the initiation of a pivotal patient clinical trial in the first half of 2018.
Read more.png)
Novartis Kisqali receives FDA Breakthrough Therapy designation
3 Jan 2018
Designation based on Phase III MONALEESA-7 results demonstrating superior efficacy of Kisqali in combination with oral endocrine therapy compared to oral endocrine therapy in pre- or perimenopausal women who received no prior endocrine therapy for adva...
Read more.png)
Scholar Rock announces $47 million Series C financing to advance innovative pipeline
3 Jan 2018
SRK-015 to move into clinical development for Spinal Muscular Atrophy (SMA) in first half of 2018; development in additional neuromuscular disorders to follow.
Read more.png)
Novel Sorrento CAR-T technology a potential “game-changer
2 Jan 2018
Company envisions the development and IND filings of multiple “next-frontier” CAR-T programs in 2018 and beyond, which will position the company as a potential major player in the fast-growing CAR-T space of immunotherapies against cancers.
Read more
Novartis' combination therapy Tafinlar + Mekinist granted FDA Priority Review
1 Jan 2018
If approved, Tafinlar + Mekinist expected to be the first adjuvant targeted therapy combination to demonstrate a significant clinical benefit in patients with a BRAF V600 mutation.
Read more
FDA accepts NDA filing for Epidiolex in the treatment of Lennox-Gastaut syndrome and Dravet syndrome
28 Dec 2017
The PDUFA goal date for completion of the FDA review of the Epidiolex NDA is 27 June 2018.
Read more
Novartis drug Tasigna approved by FDA
28 Dec 2017
First and only CML therapy with Treatment-free Remission data in its label.
Read more
MAA submitted to EMA for patisiran for the treatment of hereditary ATTR amyloidosis
27 Dec 2017
Sanofi and Alnylam's patisiran MAA to be reviewed under accelerated assessment.
Read more
AMSBIO introduces highly efficient substrate for culturing ES/iPS cells
27 Dec 2017
iMatrix recombinant Laminin-511 E8 protein fragments permit ES/iPS cells to be maintained in xeno-free, feeder-free culture conditions enabling easy application in medical trials.
Read more